Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Maprotiline→

Maprotiline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10262-69-8
Molecular formula
C20H23N
Molecular weight
277.4033 g/mol
Drug class
Tetracyclic antidepressantpredominantly norepinephrine reuptake inhibitor
Mechanism of action
Inhibits neuronal reuptake of norepinephrine, increasing noradrenergic neurotransmission. It also has antihistaminic and anticholinergic receptor effects contributing to sedation and adverse effects.
Indications / reported uses
  • Historical treatment of depressive illness in adults in countries where maprotiline remains authorised; current availability is limited and product-specific indications should be verified

Sources: NLM MeSH — Maprotiline · PubMed — Maprotiline norepinephrine reuptake pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Maprotiline Environmental Risk Assessment (ERA) (the Maprotiline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.